GRACEcast-084_Lung-Cancer_ALK Inhibition: Science and Early Clinical Experience by Dr. Ben Solomon

http://cancergrace.org/

Dr. Ben Solomon of Peter MacCallum Cancer Centre in Melbourne Australia reviews ALK Inhibition from mechanism of action to activity and side effect profile of crizotinib, newly approved for patients with ALK-positive advanced non-small cell lung cancer.

• Catégorie